Sandbox: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
== == | ==Flaws in cholesterol risk calculator?== | ||
[http://www.nytimes.com/2013/11/18/health/risk-calculator-for-cholesterol-appears-flawed.html Risk calculator for cholesterol appears flawed]<br> | [http://www.nytimes.com/2013/11/18/health/risk-calculator-for-cholesterol-appears-flawed.html Risk calculator for cholesterol appears flawed]<br> | ||
by Gina Kolata, ''New York Times'', 17 November 2013 | by Gina Kolata, ''New York Times'', 17 November 2013 | ||
Revision as of 21:00, 18 November 2013
Flaws in cholesterol risk calculator?
Risk calculator for cholesterol appears flawed
by Gina Kolata, New York Times, 17 November 2013
The article links to the following graphic summarizing the findings
For commentary on a related story, see the post The Economics & Politics of Drugs for Mild Hypertension from HealthNewsReview.org (4 November 2013), which begins
The Cochrane Collaboration’s Hypertension Group published a systematic review of drug treatment for mild hypertension in August 2012 showing no evidence that drugs benefit patients while about 11% have side effects severe enough to stop treatment. As coauthor of that review, I will comment on the economics, politics, regulatory intrigue, financial conflicts, and subsequent media coverage involved.
Submitted by Paul Alper